Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Table 5 Summary statistics of asthma control (assessed by ACQ) at each time point (per-protocol population)

	Baseline	6 months	12 months	Change from baseline to 6 months; p value	Change from baseline to 12 months; p value
ACQ total score	2.9 ± 1.1	1.4 ± 1.0	1.6 ± 1.1	−1.5 ± 1.2; P < 0.0001	−1.4 ± 1.1; P < 0.0001
Item 1	2.1 ± 1.6	1.0 ± 1.3	1.1 ± 1.2	−1.1 ± 1.6; P < 0.0001	−1.0 ± 1.7; P < 0.0001
Item 2	3.1 ± 1.7	1.3 ± 1.2	1.5 ± 1.4	−1.8 ± 1.8; P < 0.0001	−1.6 ± 1.9; P < 0.0001
Item 3	3.2 ± 1.4	1.3 ± 1.2	1.5 ± 1.3	−1.9 ± 1.7; P < 0.0001	−1.7 ± 1.7; P < 0.0001
Item 4	3.7 ± 1.6	1.7 ± 1.5	1.8 ± 1.5	−1.9 ± 1.9; P < 0.0001	−1.9 ± 1.8; P < 0.0001
Item 5	3.1 ± 1.8	1.4 ± 1.5	1.6 ± 1.7	−1.7 ± 1.7; P < 0.0001	−1.6 ± 1.9; P < 0.0001
Item 6	1.4 ± 1.2	0.6 ± 1.0	0.6 ± 0.9	−0.8 ± 1.4; P < 0.0001	−0.7 ± 1.2; P < 0.0001
FEV₁ pre-bronchodilator (L)	1.7 ± 0.7	2.1 ± 0.9	2.2 ± 1.1	0.4 ± 0.6; P < 0.0001	0.4 ± 0.9; P < 0.0001
Item 7	4.2 ± 1.6	3.0 ± 2.0	3.0 ± 2.0	−1.2 ± 1.8; P < 0.0001	−1.2 ± 2.1; P < 0.0001

Data are presented as mean ± SD
ACQ total score was evaluated using Paired sample t-test; ACQ individual component scores were evaluated using Signed Rank test
P < 0.05 is considered statistically significant
ACQ Asthma Control Questionnaire

ISSN: 1939-4551